Twist of fate for acute promyelocytic leukemia: Trib3–TwIst1 interaction promotes resistance

Stephen Z. Peeke; Kira Gritsman

doi:10.1158/1078-0432.CCR-19-2140

Twist of fate for acute promyelocytic leukemia: Trib3–TwIst1 interaction promotes resistance

Stephen Z. Peeke, Kira Gritsman

Oncology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance.

Original language	English (US)
Pages (from-to)	6018-6020
Number of pages	3
Journal	Clinical Cancer Research
Volume	25
Issue number	20
DOIs	https://doi.org/10.1158/1078-0432.CCR-19-2140
State	Published - Oct 15 2019

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-19-2140

Cite this

@article{bfc462df678a405cafcfd3778e9f3378,

title = "Twist of fate for acute promyelocytic leukemia: Trib3–TwIst1 interaction promotes resistance",

abstract = "While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance.",

author = "Peeke, {Stephen Z.} and Kira Gritsman",

note = "Funding Information: This work was supported by NCI R01 CA196973 (to K. Gritsman). Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = oct,

day = "15",

doi = "10.1158/1078-0432.CCR-19-2140",

language = "English (US)",

volume = "25",

pages = "6018--6020",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "20",

}

TY - JOUR

T1 - Twist of fate for acute promyelocytic leukemia

T2 - Trib3–TwIst1 interaction promotes resistance

AU - Peeke, Stephen Z.

AU - Gritsman, Kira

PY - 2019/10/15

Y1 - 2019/10/15

N2 - While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance.

AB - While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance.

UR - http://www.scopus.com/inward/record.url?scp=85073307158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073307158&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-19-2140

DO - 10.1158/1078-0432.CCR-19-2140

M3 - Article

C2 - 31405833

AN - SCOPUS:85073307158

SN - 1078-0432

VL - 25

SP - 6018

EP - 6020

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 20

ER -

Twist of fate for acute promyelocytic leukemia: Trib3–TwIst1 interaction promotes resistance

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this